REPL
Replimune Group, Inc. NASDAQ Listed Jul 20, 2018$11.18
After hrs
$11.01
-1.52%
Mkt Cap $900.7M
52w Low $1.70
86.7% of range
52w High $12.63
50d MA $5.35
200d MA $7.08
P/E (TTM)
-3.1x
EV/EBITDA
—
P/B
2.2x
Debt/Equity
0.2x
ROE
-119.6%
P/FCF
-4.5x
RSI (14)
67.10
ATR (14)
$0.89
Beta
0.74
50d MA
$5.35
200d MA
$7.08
Avg Volume
7.1M
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
500 Unicorn Park Drive · Woburn, MA 01801 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2026 | BMO | -0.77 | -0.77 | -0.2% | 7.38 | +1.1% | -5.1% | -1.0% | +11.8% | +0.4% | +0.3% | — |
| Nov 6, 2025 | BMO | -0.87 | -0.90 | -3.4% | 8.50 | -3.3% | -2.2% | +4.8% | +4.8% | -1.0% | -0.7% | — |
| Aug 7, 2025 | BMO | -0.83 | -0.95 | -14.5% | 5.48 | -1.6% | -3.5% | -5.7% | +5.2% | -3.0% | +5.1% | — |
| May 22, 2025 | BMO | -0.75 | -0.82 | -9.3% | 8.76 | -0.6% | -4.7% | +0.8% | +0.1% | +11.2% | -4.2% | — |
| Feb 12, 2025 | BMO | -0.70 | -0.79 | -12.9% | 13.79 | -0.7% | +3.6% | -1.3% | -0.5% | -1.8% | +3.8% | — |
| Nov 12, 2024 | BMO | -0.75 | -0.68 | +9.3% | 12.19 | -0.1% | -4.1% | -2.5% | -5.3% | -0.3% | +1.7% | — |
| Aug 8, 2024 | BMO | -0.88 | -0.78 | +11.4% | 9.45 | +0.5% | +1.4% | -0.3% | +1.9% | +1.3% | +4.5% | — |
| May 16, 2024 | BMO | -0.86 | -0.82 | +4.7% | 6.72 | +1.0% | -4.2% | -7.8% | -6.2% | +6.5% | -4.6% | — |
| Feb 8, 2024 | BMO | -0.94 | -0.77 | +18.1% | 7.72 | +5.8% | +0.5% | +2.4% | -9.9% | -4.1% | +11.5% | — |
| Nov 7, 2023 | BMO | -0.80 | -0.90 | -12.5% | 10.83 | +1.2% | +6.6% | -0.5% | -3.2% | -3.5% | +4.7% | — |
| Aug 3, 2023 | BMO | -0.85 | -0.75 | +11.8% | 19.25 | -0.5% | +2.8% | -4.2% | -3.4% | +3.6% | +2.8% | — |
| May 18, 2023 | BMO | -0.66 | -0.74 | -12.1% | 19.64 | +0.4% | -0.3% | +0.6% | -1.2% | -2.3% | +1.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 29 | JP Morgan | Upgrade | Underweight → Neutral | $8 | $4.68 | $7.93 | +69.4% | +85.7% | +3.6% | -1.4% | +12.5% | -1.1% |
| Apr 13 | Wedbush | Downgrade | Outperform → Neutral | — | $4.76 | $1.71 | -64.1% | -64.3% | +14.7% | +16.9% | -3.9% | -0.9% |
| Apr 13 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $4.76 | $1.71 | -64.1% | -64.3% | +14.7% | +16.9% | -3.9% | -0.9% |
| Apr 13 | JP Morgan | Downgrade | Neutral → Underweight | — | $4.76 | $1.71 | -64.1% | -64.3% | +14.7% | +16.9% | -3.9% | -0.9% |
| Apr 13 | Jefferies | Downgrade | Buy → Hold | — | $4.76 | $1.71 | -64.1% | -64.3% | +14.7% | +16.9% | -3.9% | -0.9% |
| Apr 13 | HC Wainwright & Co. | Downgrade | Buy → Sell | — | $4.76 | $1.71 | -64.1% | -64.3% | +14.7% | +16.9% | -3.9% | -0.9% |
| Apr 13 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $4.76 | $1.71 | -64.1% | -64.3% | +14.7% | +16.9% | -3.9% | -0.9% |
| Feb 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.00 | $7.03 | +0.4% | -1.0% | +11.8% | +0.4% | +0.3% | -0.5% |
| Feb 4 | Wedbush | Maintains | Outperform → Outperform | — | $7.38 | $7.46 | +1.1% | -5.1% | -1.0% | +11.8% | +0.4% | +0.3% |
| Nov 3 | BMO Capital | Upgrade | Underperform → Market Perform | — | $9.73 | $9.35 | -3.9% | -4.3% | -3.7% | -4.3% | -0.9% | -2.2% |
| Oct 27 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $8.80 | $9.29 | +5.6% | +6.0% | +12.0% | -2.3% | +0.4% | -5.1% |
| Oct 20 | Wedbush | Upgrade | Neutral → Outperform | — | $4.50 | $9.19 | +104.2% | +98.9% | -9.5% | +2.5% | +1.4% | +4.5% |
| Oct 20 | Leerink Partners | Upgrade | Market Perform → Outperform | — | $4.50 | $9.19 | +104.2% | +98.9% | -9.5% | +2.5% | +1.4% | +4.5% |
| Oct 20 | JP Morgan | Upgrade | Underweight → Neutral | — | $4.50 | $9.19 | +104.2% | +98.9% | -9.5% | +2.5% | +1.4% | +4.5% |
| Sep 19 | JP Morgan | Downgrade | Neutral → Underweight | — | $3.46 | $3.40 | -1.7% | -6.6% | +1.2% | +32.4% | -3.9% | -2.6% |
| Sep 8 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $6.33 | $6.24 | -1.4% | -4.6% | -3.6% | +2.9% | +0.3% | -4.7% |
| Jul 30 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $3.75 | $6.42 | +71.2% | +101.3% | -6.9% | +8.1% | -24.9% | +10.7% |
| Jul 23 | Barclays | Downgrade | Overweight → Equal Weight | — | $2.81 | $2.74 | -2.5% | +18.9% | -7.2% | +1.6% | +0.6% | +18.3% |
| Jul 23 | BMO Capital | Downgrade | Outperform → Underperform | — | $2.81 | $2.74 | -2.5% | +18.9% | -7.2% | +1.6% | +0.6% | +18.3% |
| Jul 23 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.81 | $2.74 | -2.5% | +18.9% | -7.2% | +1.6% | +0.6% | +18.3% |
| Jul 22 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $12.33 | $2.71 | -78.0% | -77.2% | +18.9% | -7.2% | +1.6% | +0.6% |
| Jul 22 | JP Morgan | Downgrade | Overweight → Neutral | — | $12.33 | $2.71 | -78.0% | -77.2% | +18.9% | -7.2% | +1.6% | +0.6% |
| Jul 22 | Wedbush | Downgrade | Outperform → Neutral | — | $12.33 | $2.71 | -78.0% | -77.2% | +18.9% | -7.2% | +1.6% | +0.6% |
| Jul 22 | Jefferies | Maintains | Buy → Buy | — | $12.33 | $2.71 | -78.0% | -77.2% | +18.9% | -7.2% | +1.6% | +0.6% |
| Jul 16 | JP Morgan | Maintains | Overweight → Overweight | — | $12.40 | $13.19 | +6.4% | +1.9% | -1.0% | -3.3% | +2.0% | -77.2% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.55 | $9.70 | +1.6% | -1.6% | +2.7% | -3.2% | +11.2% | +3.7% |
| Jun 2 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.98 | $9.28 | +3.3% | +6.6% | +0.6% | +0.6% | +0.6% | +6.5% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $13.49 | $13.83 | +2.5% | -1.9% | -4.5% | +0.3% | -4.4% | -0.8% |
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.79 | $13.70 | -0.7% | +3.6% | -1.3% | -0.5% | -1.8% | +3.8% |
| Jan 22 | BMO Capital | Maintains | Outperform → Outperform | — | $11.85 | $12.23 | +3.2% | +9.9% | +5.6% | -1.2% | +0.7% | +2.4% |
| Jan 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.85 | $12.23 | +3.2% | +9.9% | +5.6% | -1.2% | +0.7% | +2.4% |
| Dec 4 | Jefferies | Maintains | Buy → Buy | — | $13.14 | $13.40 | +2.0% | +0.2% | -0.9% | +0.2% | -3.4% | +1.6% |
| Nov 22 | BMO Capital | Maintains | Outperform → Outperform | — | $11.05 | $13.68 | +23.8% | +35.1% | -11.2% | +8.4% | -2.3% | +0.2% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.05 | $13.68 | +23.8% | +35.1% | -11.2% | +8.4% | -2.3% | +0.2% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.50 | $12.49 | -0.1% | -2.5% | -4.1% | -2.5% | -5.3% | -0.3% |
| Sep 24 | JP Morgan | Maintains | Overweight → Overweight | — | $10.96 | $11.20 | +2.2% | +1.0% | +0.0% | +0.5% | +0.3% | -1.8% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.13 | $11.23 | +0.9% | -6.0% | +5.4% | +0.5% | +1.4% | -2.8% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.53 | $10.55 | +0.2% | -1.8% | +0.3% | +0.1% | +7.2% | -6.0% |
| Aug 13 | JP Morgan | Maintains | Overweight → Overweight | — | $9.55 | $9.32 | -2.4% | +1.9% | +1.3% | +4.5% | -1.8% | +1.7% |
| Jun 7 | Barclays | Maintains | Overweight → Overweight | — | $7.11 | $7.26 | +2.1% | +11.1% | +13.9% | +0.0% | -2.0% | +7.3% |
| Jun 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.11 | $7.26 | +2.1% | +11.1% | +13.9% | +0.0% | -2.0% | +7.3% |
| Dec 6 | Barclays | Maintains | Overweight → Overweight | — | $6.75 | $6.80 | +0.7% | +9.0% | +3.3% | -4.1% | +2.2% | -0.8% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.11 | $11.07 | -0.4% | -3.5% | +4.7% | -0.5% | -7.5% | +0.8% |
| Nov 8 | Wedbush | Maintains | Outperform → Outperform | — | $10.83 | $10.96 | +1.2% | +6.6% | -0.5% | -3.2% | -3.5% | +4.7% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.79 | $19.92 | +0.7% | -4.2% | -3.4% | +3.6% | +2.8% | +2.3% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.07 | $21.10 | +0.1% | -2.5% | +3.8% | -9.7% | +2.8% | -4.2% |
| Jun 15 | JP Morgan | Maintains | Overweight → Overweight | — | $23.48 | $24.60 | +4.8% | +2.3% | -0.7% | -0.8% | -0.7% | +0.2% |
| Jun 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.85 | $22.78 | -0.3% | -1.3% | -0.4% | +4.4% | +2.8% | -2.6% |
| Jun 7 | EF Hutton | Maintains | Buy → Buy | — | $23.63 | $23.86 | +1.0% | -3.3% | -1.3% | -0.4% | +4.4% | +2.8% |
| Jun 7 | Wedbush | Maintains | Outperform → Outperform | — | $23.63 | $23.86 | +1.0% | -3.3% | -1.3% | -0.4% | +4.4% | +2.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Sarchi ChristopherOff | Chief Commercial Officer | Sell | 12,000 | $9.24 | $111K | 180,962 | -1.10% | -8.33% |
| May 18, 2026 | Patel SushilDir/Off | Chief Executive Officer | Sell | 37,324 | $5.08 | $190K | 747,492 | +1.16% | -0.43% |
| May 18, 2026 | Schwendenman AndrewOff | Chief Accounting Officer | Sell | 7,894 | $5.08 | $40K | 107,057 | +1.16% | -0.43% |
| May 18, 2026 | Sarchi ChristopherOff | Chief Commercial Officer | Sell | 8,626 | $5.08 | $44K | 192,962 | +1.16% | -0.43% |
| May 18, 2026 | Xynos KonstantinosOff | Chief Medical Officer | Sell | 14,023 | $5.08 | $71K | 235,662 | +1.16% | -0.43% |
| May 18, 2026 | Hill Emily LuisaOff | Chief Financial Officer | Sell | 7,812 | $5.08 | $40K | 236,556 | +1.16% | -0.43% |
| May 18, 2026 | Astley-Sparke PhilipDir | — | Sell | 17,657 | $5.08 | $90K | 1,412,414 | +1.16% | -0.43% |
8-K · 7.01
! Medium
Replimune Group, Inc. -- 8-K 7.01: Regulation FD Disclosure
May 29
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Replimune's RP1 oncolytic virus therapy failed FDA approval, dealing a significant setback to the company's pipeline and likely pressuring the stock given the treatment was a key revenue driver candidate.
Apr 13
8-K · 1.01
!! High
Replimune Group, Inc. -- 8-K 1.01: Material Agreement
Replimune secured an additional $30 million in funding from Hercules Capital through a loan amendment, providing financial flexibility for the biotech company's clinical development programs.
Feb 3
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Rtw Investments, Lp | 7,356,916 | $56M | Added | Mar 2026 |
| 2 | Toronto Dominion Bank | 2,229,527 | $22M | Added | Dec 2025 |
| 3 | Vanguard Capital Management Llc | 2,759,120 | $21M | New | Mar 2026 |
| 4 | D.e. Shaw & Co | 2,336,528 | $18M | Reduced | Mar 2026 |
| 5 | Morgan Stanley | 1,629,776 | $16M | Reduced | Dec 2025 |
| 6 | Fmr Llc | 2,045,490 | $16M | Reduced | Mar 2026 |
| 7 | Adar1 Capital Management, Llc | 1,582,987 | $12M | New | Mar 2026 |
| 8 | Jpmorgan Chase & Co | 789,951 | $6M | Reduced | Mar 2026 |
| 9 | Jane Street Group, Llc | 584,330 | $6M | — | Dec 2025 |
| 10 | Susquehanna International Group, Llp | 623,979 | $5M | Added | Mar 2026 |
| 11 | Northern Trust Corp | 589,120 | $5M | Added | Mar 2026 |
| 12 | Ubs Group Ag | 581,210 | $4M | Reduced | Mar 2026 |
| 13 | Boxer Capital Management, Llc | 1,050,000 | $4M | Reduced | Sep 2025 |
| 14 | Vanguard Portfolio Management Llc | 552,576 | $4M | New | Mar 2026 |
| 15 | Citadel Advisors Llc | 398,729 | $3M | Added | Mar 2026 |
| 16 | Renaissance Technologies Llc | 381,453 | $3M | Reduced | Mar 2026 |
| 17 | Woodline Partners Lp | 380,988 | $3M | Reduced | Mar 2026 |
| 18 | Two Sigma Investments, Lp | 344,751 | $3M | Reduced | Mar 2026 |
| 19 | Millennium Management | 300,833 | $2M | Reduced | Mar 2026 |
| 20 | Caption Management, Llc | 228,570 | $2M | Added | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$900.7M
Enterprise Value
$463.3M
P/E (TTM)
-3.12x
Forward P/E
—
PEG Ratio
0.61x
P/B
2.17x
P/S
—
P/FCF
-4.53x
EV/EBITDA
—
Shares Out
80.6M
Financials (TTM)
Revenue
$0
Net Income
-$314.9M
EBITDA
-$311.4M
Free Cash Flow
-$198.9M
Op Cash Flow
-$192.2M
EPS Basic
$-3.07
EPS Diluted
$-3.58
EPS Forward
$-1.63
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$551.3M
Total Liab.
$135.5M
Total Equity
$415.8M
Cash
$483.8M
LT Debt
$46.4M
Book Value/Sh
$5.16
Debt/Equity
0.18x
Current Ratio
7.95
Quick Ratio
7.95
Returns & Growth
ROE
-119.6%
ROA
-75.5%
ROIC
-53.1%
Rev Growth YoY
+0.0%
EPS Growth YoY
+5.2%
Price Returns
2W
+76.3%
1M
+238.1%
3M
+13.6%
6M
-13.1%
12M
-3.2%
Technicals
52W High
$12.63
52W Low
$1.70
50d MA
$5.35
200d MA
$7.08
RSI (14)
67.10
ATR (14)
$0.89
Beta
0.74
Avg Volume
7.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$12.50
High
$14.00
Low
$11.00
Median
$12.50
Data updated apr 26, 2026 10:28pm
· Source: financialmodelingprep.com